{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T12:13:56Z","timestamp":1793708036947,"version":"4.6.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The study is supported through funding from the Children\u2019s Oncology Group\u2014Alexis and Jerry Bednyak Foundation Award for Research in High-Risk Leukemia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41375-025-02748-7","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:19:42Z","timestamp":1757506782000},"page":"2721-2734","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Longitudinal single-cell analysis reveals treatment-resistant stem and mast cells with potential treatments for pediatric AML"],"prefix":"10.1038","volume":"39","author":[{"given":"Denis","family":"Ohlstrom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Bakhtiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Mumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-2913","authenticated-orcid":false,"given":"Alejandro","family":"De Janon Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-9006","authenticated-orcid":false,"given":"Deborah","family":"DeRyckere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Chien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Pilcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2639-6269","authenticated-orcid":false,"given":"Sean","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6201-6900","authenticated-orcid":false,"given":"Douglas","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-1459","authenticated-orcid":false,"given":"Swati","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"2748_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"2748_CR2","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10555-020-09846-1","volume":"39","author":"SE Conneely","year":"2020","unstructured":"Conneely SE, Rau RE. The genomics of acute myeloid leukemia in children. Cancer Metastasis Rev. 2020;39:189\u2013209.","journal-title":"Cancer Metastasis Rev"},{"key":"2748_CR3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/s41375-023-01931-y","volume":"37","author":"L Lew-Derivry","year":"2023","unstructured":"Lew-Derivry L, Marceau-Renaut A, Fenwarth L, Cuccuini W, Ballerini P, Ferreboeuf M, et al. Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group. Leukemia. 2023;37:1723\u20136.","journal-title":"Leukemia"},{"key":"2748_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-01009-3","volume":"23","author":"SE Conneely","year":"2021","unstructured":"Conneely SE, Stevens AM. Acute myeloid leukemia in children: emerging paradigms in genetics and new approaches to therapy. Curr Oncol Rep. 2021;23:16.","journal-title":"Curr Oncol Rep"},{"key":"2748_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10965-5","volume":"23","author":"K Qiu","year":"2023","unstructured":"Qiu K, Liao X, Li Y, Huang K, Xu H, Fang J, et al. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16). BMC Cancer. 2023;23:476.","journal-title":"BMC Cancer"},{"key":"2748_CR6","doi-asserted-by":"crossref","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4:27\u201342.","DOI":"10.1038\/s43018-023-00518-x"},{"key":"2748_CR7","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140179","volume":"5","author":"JK Bailur","year":"2020","unstructured":"Bailur JK, McCachren SS, Pendleton K, Vasquez JC, Lim HS, Duffy A, et al. Risk-associated alterations in marrow T cells in pediatric leukemia. JCI Insight. 2020;5:e140179.","journal-title":"JCI Insight"},{"key":"2748_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ccell.2023.10.008","volume":"41","author":"S Lambo","year":"2023","unstructured":"Lambo S, Trinh DL, Ries RE, Jin D, Setiadi A, Ng M, et al. A longitudinal single-cell atlas of treatment response in pediatric AML. Cancer Cell. 2023;41:2117\u20132135.e12.","journal-title":"Cancer Cell"},{"key":"2748_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41994-0","volume":"14","author":"H Mumme","year":"2023","unstructured":"Mumme H, Thomas BE, Bhasin SS, Krishnan U, Dwivedi B, Perumalla P, et al. Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia. Nat Commun. 2023;14:6209.","journal-title":"Nat Commun"},{"key":"2748_CR10","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A Van Rhenen","year":"2005","unstructured":"Van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520\u20137.","journal-title":"Clin Cancer Res"},{"key":"2748_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41375-019-0604-8","volume":"34","author":"AH Elsayed","year":"2020","unstructured":"Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, et al. A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia. 2020;34:735\u201345.","journal-title":"Leukemia"},{"key":"2748_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03031-7","volume":"24","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Jiang S, He F, Tian Y, Hu H, Gao L, et al. Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML. Genome Biol. 2023;24:199.","journal-title":"Genome Biol"},{"key":"2748_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.exphem.2018.09.004","volume":"68","author":"SB Hay","year":"2018","unstructured":"Hay SB, Ferchen K, Chetal K, Grimes HL, Salomonis N. The Human Cell Atlas bone marrow single-cell interactive web portal. Exp Hematol. 2018;68:51\u201361.","journal-title":"Exp Hematol"},{"key":"2748_CR14","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.leukres.2013.08.010","volume":"37","author":"ST Pullarkat","year":"2013","unstructured":"Pullarkat ST, Pullarkat V, Lagoo A, Brynes R, Weiss LM, Bedell V, et al. Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1. Leuk Res. 2013;37:1572\u20135.","journal-title":"Leuk Res"},{"key":"2748_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2023-180275","volume":"142","author":"JA Cook","year":"2023","unstructured":"Cook JA, Lott L, Perry J, Nalla A, Xu D, Hudson CA, et al. Residual mast cells can explain persistent molecular positivity in difference from normal flow cytometric-defined MRD negative core binding factor AML. Blood. 2023;142:426\u2013426.","journal-title":"Blood"},{"key":"2748_CR16","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/pbc.23026","volume":"57","author":"KM Mahadeo","year":"2011","unstructured":"Mahadeo KM, Wolgast L, McMahon C, Cole PD. Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. Pediatr Blood Cancer. 2011;57:684\u20137.","journal-title":"Pediatr Blood Cancer"},{"key":"2748_CR17","doi-asserted-by":"publisher","first-page":"854","DOI":"10.4103\/0377-4929.91531","volume":"54","author":"S Sharma","year":"2011","unstructured":"Sharma S, Harbhajanka A, Jain A, Seth A. Systemic mastocytosis with an associated non mast cell lineage clonal hematological disease in a child. Indian J Pathol Microbiol. 2011;54:854\u20136.","journal-title":"Indian J Pathol Microbiol"},{"key":"2748_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4103\/0377-4929.188140","volume":"59","author":"N Rabade","year":"2016","unstructured":"Rabade N, Tembhare P, Patkar N, Amare P, Arora B, Subramanian P, et al. Childhood systemic mastocytosis associated with t (8; 21) (q22; q22) acute myeloid leukemia. Indian J Pathol Microbiol. 2016;59:407.","journal-title":"Indian J Pathol Microbiol"},{"key":"2748_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/pbc.24250","volume":"59","author":"M Yabe","year":"2012","unstructured":"Yabe M, Masukawa A, Kato S, Yabe H, Nakamura N, Matsushita H. Systemic mastocytosis associated with t(8;21) acute myeloid leukemia in a child: Detection of the D816A mutation of KIT. Pediatr Blood Cancer. 2012;59:1313\u20136.","journal-title":"Pediatr Blood Cancer"},{"key":"2748_CR20","doi-asserted-by":"publisher","first-page":"e372","DOI":"10.1097\/MPH.0b013e3182329b80","volume":"33","author":"S Intzes","year":"2011","unstructured":"Intzes S, Wiersma S, Meyerson HJ. Myelomastocytic leukemia with t(8;21) in a 3-year-old child. J Pediatr Hematol Oncol. 2011;33:e372\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2748_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/MPH.0b013e318253f060","volume":"35","author":"A Gogia","year":"2013","unstructured":"Gogia A, Sharawat SK, Kumar R, Sarkar C, Bakhshi S. Systemic mastocytosis associated with childhood acute myeloid leukemia. J Pediatr Hematol Oncol. 2013;35:163\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2748_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30898","volume":"71","author":"IN Sheikh","year":"2024","unstructured":"Sheikh IN, AlQahtani S, Yin CC, McCall D, Cuglievan B, Ragoonanan D, et al. KIT \u2010mutated pediatric core\u2010binding factor systemic mastocytosis\u2010acute myeloid leukemia treated with avapritinib and decitabine. Pediatr Blood Cancer. 2024;71:e30898.","journal-title":"Pediatr Blood Cancer"},{"key":"2748_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 2019;8:329\u2013337.e4.","journal-title":"Cell Syst"},{"key":"2748_CR24","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u20133587.e29.","journal-title":"Cell"},{"key":"2748_CR25","unstructured":"Ticle T, Tirosh I, Georgescu C, Brown M, Haas B. inferCNV of the Trinity CTAT Project. 2019. https:\/\/github.com\/broadinstitute\/inferCNV."},{"key":"2748_CR26","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/cam4.5026","volume":"12","author":"K Yuen","year":"2023","unstructured":"Yuen K, Liu Y, Zhou Y, Wang Y, Zhou D, Fang J, et al. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23\/ KMT2A rearrangements. Cancer Med. 2023;12:1418\u201330.","journal-title":"Cancer Med"},{"key":"2748_CR27","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90\u20137.","journal-title":"Nucleic Acids Res"},{"key":"2748_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/9982192","volume":"2021","author":"F Jiang","year":"2021","unstructured":"Jiang F, Wang X-Y, Wang M-Y, Mao Y, Miao X-L, Wu C-Y, et al. An immune checkpoint-related gene signature for predicting survival of pediatric acute myeloid leukemia. J Oncol. 2021;2021:1\u201314.","journal-title":"J Oncol"},{"key":"2748_CR29","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.3390\/biom12101359","volume":"12","author":"Y Gao","year":"2022","unstructured":"Gao Y, Zhou J-F, Mao J-Y, Jiang L, Li X-P. Identification of the thyrotropin-releasing hormone (TRH) as a novel biomarker in the prognosis for acute myeloid leukemia. Biomolecules. 2022;12:1359.","journal-title":"Biomolecules"},{"key":"2748_CR30","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1080\/15384047.2019.1638663","volume":"20","author":"Z Cheng","year":"2019","unstructured":"Cheng Z, Dai Y, Pang Y, Jiao Y, Liu Y, Cui L, et al. High EGFL7 expression may predict poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Cancer Biol Ther. 2019;20:1314\u20138.","journal-title":"Cancer Biol Ther"},{"key":"2748_CR31","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1182\/blood-2007-11-124958","volume":"111","author":"C Langer","year":"2008","unstructured":"Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mr\u00f3zek K, et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008;111:5371\u20139.","journal-title":"Blood"},{"key":"2748_CR32","doi-asserted-by":"crossref","unstructured":"Majoros A, Platanitis E, Kernbauer-H\u00f6lzl E, Rosebrock F, M\u00fcller M, Decker T. Canonical and non-canonical aspects of JAK\u2013STAT signaling: lessons from interferons for cytokine responses. Front Immunol. 2017;8:29.","DOI":"10.3389\/fimmu.2017.00029"},{"key":"2748_CR33","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.1016\/j.vaccine.2009.05.010","volume":"27","author":"M Piesche","year":"2009","unstructured":"Piesche M, Hildebrandt Y, Chapuy B, Wulf GG, Tr\u00fcmper L, Schroers R. Characterization of HLA-DR-restricted T-cell epitopes derived from human proteinase 3. Vaccine. 2009;27:4718\u201323.","journal-title":"Vaccine"},{"key":"2748_CR34","doi-asserted-by":"crossref","unstructured":"Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M et al. Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proc Natl Acad Sci. 2017;114:E4641\u20137.","DOI":"10.1073\/pnas.1703142114"},{"key":"2748_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3892\/mco.2017.1129","volume":"6","author":"A Nicolussi","year":"2017","unstructured":"Nicolussi A, D\u2019Inzeo S, Capalbo C, Giannini G, Coppa A. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017;6:139\u201353.","journal-title":"Mol Clin Oncol"},{"key":"2748_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad142","volume":"24","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen X, Chen J, Qi X. Decoding Connectivity Map-based drug repurposing for oncotherapy. Brief Bioinform. 2023;24:bbad142.","journal-title":"Brief Bioinform"},{"key":"2748_CR37","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1182\/blood-2014-01-551234","volume":"124","author":"Z Guo","year":"2014","unstructured":"Guo Z, Wang A, Zhang W, Levit M, Gao Q, Barberis C, et al. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene. Blood. 2014;124:1777\u201389.","journal-title":"Blood"},{"key":"2748_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"2748_CR39","first-page":"442","volume":"14","author":"L Yang","year":"2006","unstructured":"Yang L, Dong Z-R, Pan L, Luo J-M, Xu S-R. Expression of midkine in patients with acute myeloid leukemia and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006;14:442\u20135.","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"2748_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32673-7","volume":"13","author":"Y Tang","year":"2022","unstructured":"Tang Y, Kwiatkowski DJ, Henske EP. Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment. Nat Commun. 2022;13:5018.","journal-title":"Nat Commun"},{"key":"2748_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15770-3","volume":"11","author":"X Guo","year":"2020","unstructured":"Guo X, Pan Y, Xiong M, Sanapala S, Anastasaki C, Cobb O, et al. Midkine activation of CD8+ T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth. Nat Commun. 2020;11:2177.","journal-title":"Nat Commun"},{"key":"2748_CR42","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ. Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev. 2019;34:26\u201333.","journal-title":"Blood Rev"},{"key":"2748_CR43","doi-asserted-by":"crossref","unstructured":"Yan H, He D, Huang X, Zhang E, Chen Q, Xu R et al. Role of interleukin\u201132 in cancer biology. Oncol Lett. 2018:41\u20137.","DOI":"10.3892\/ol.2018.8649"},{"key":"2748_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.837590","volume":"13","author":"S Shim","year":"2022","unstructured":"Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, et al. A paradoxical effect of interleukin-32 isoforms on cancer. Front Immunol. 2022;13:837590.","journal-title":"Front Immunol"},{"key":"2748_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbac014","volume":"5","author":"M Yang","year":"2022","unstructured":"Yang M, Lin C, Wang Y, Chen K, Han Y, Zhang H, et al. Cytokine storm promoting T cell exhaustion in severe COVID-19 revealed by single cell sequencing data analysis. Precis Clin Med. 2022;5:pbac014.","journal-title":"Precis Clin Med"},{"key":"2748_CR46","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3324\/haematol.2019.222612","volume":"105","author":"B Depreter","year":"2020","unstructured":"Depreter B, Weening KE, Vandepoele K, Essand M, De Moerloose B, Themeli M, et al. TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment. Haematologica. 2020;105:1306\u201316.","journal-title":"Haematologica"},{"key":"2748_CR47","doi-asserted-by":"publisher","first-page":"33542","DOI":"10.1074\/jbc.M113.511170","volume":"288","author":"S Pei","year":"2013","unstructured":"Pei S, Minhajuddin M, Callahan KP, Balys M, Ashton JM, Neering SJ, et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J Biol Chem. 2013;288:33542\u201358.","journal-title":"J Biol Chem"},{"key":"2748_CR48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.65150","volume":"10","author":"S McGuirk","year":"2021","unstructured":"McGuirk S, Audet-Delage Y, Annis MG, Xue Y, Vernier M, Zhao K, et al. Resistance to different anthracycline chemotherapeutics elicits distinct and actionable primary metabolic dependencies in breast cancer. eLife. 2021;10:e65150.","journal-title":"eLife"},{"key":"2748_CR49","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/0006-2952(90)90151-A","volume":"39","author":"S Nair","year":"1990","unstructured":"Nair S, Singh SV, Samy TSA, Krishan A. Anthracycline resistance in murine leukemic P388 CELLS. Biochem Pharm. 1990;39:723\u20138.","journal-title":"Biochem Pharm"},{"key":"2748_CR50","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.1074\/jbc.272.12.7883","volume":"272","author":"J Chaudhuri","year":"1997","unstructured":"Chaudhuri J, Si K, Maitra U. Function of eukaryotic translation initiation factor 1A (eIF1A) (formerly called eIF-4C) in initiation of protein synthesis. J Biol Chem. 1997;272:7883\u201391.","journal-title":"J Biol Chem"},{"key":"2748_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110144","volume":"87","author":"X Yang","year":"2021","unstructured":"Yang X, Wan M, Yu F, Wu X. Histone methyltransferase EZH2 epigenetically affects CCNA1 expression in acute myeloid leukemia. Cell Sig. 2021;87:110144.","journal-title":"Cell Sig"},{"key":"2748_CR52","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2024025618","volume":"145","author":"B Cui","year":"2025","unstructured":"Cui B, Ai L, Lei M, Duan Y, Tang C, Zhang J, et al. Single-cell epigenetic and clonal analysis decodes disease progression in pediatric acute myeloid leukemia. Blood. 2025;145:1211\u201324.","journal-title":"Blood"},{"key":"2748_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35192-7","volume":"13","author":"N Berastegui","year":"2022","unstructured":"Berastegui N, Ainciburu M, Romero JP, Garcia-Olloqui P, Alfonso-Pierola A, Philippe C, et al. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes. Nat Commun. 2022;13:7619.","journal-title":"Nat Commun"},{"key":"2748_CR54","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1182\/blood.2020007899","volume":"137","author":"VA Gupta","year":"2021","unstructured":"Gupta VA, Barwick BG, Matulis SM, Shirasaki R, Jaye DL, Keats JJ, et al. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. Blood. 2021;137:3604\u201315.","journal-title":"Blood"},{"key":"2748_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000346","volume":"4","author":"B Depreter","year":"2020","unstructured":"Depreter B, De Moerloose B, Vandepoele K, Uyttebroeck A, Van Damme A, Denys B, et al. Clinical significance of TARP expression in pediatric acute myeloid leukemia. HemaSphere. 2020;4:e346.","journal-title":"HemaSphere"},{"key":"2748_CR56","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/leu.2010.61","volume":"24","author":"JM Fortier","year":"2010","unstructured":"Fortier JM, Payton JE, Cahan P, Ley TJ, Walter MJ, Graubert TA. POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature. Leukemia. 2010;24:950\u20137.","journal-title":"Leukemia"},{"key":"2748_CR57","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2004-03-1154","volume":"104","author":"ME Ross","year":"2004","unstructured":"Ross ME, Mahfouz R, Onciu M, Liu H-C, Zhou X, Song G, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104:3679\u201387.","journal-title":"Blood"},{"key":"2748_CR58","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.18632\/oncotarget.4213","volume":"6","author":"A Chatterjee","year":"2015","unstructured":"Chatterjee A, Ghosh J, Kapur R. Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget. 2015;6:18250\u201364.","journal-title":"Oncotarget"},{"key":"2748_CR59","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stemcr.2019.05.007","volume":"13","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhang Y, Chen B, Dong Y, Zhang Y, Mao B, et al. Overexpression of GATA2 enhances development and maintenance of human embryonic stem cell-derived hematopoietic stem cell-like progenitors. Stem Cell Rep. 2019;13:31\u201347.","journal-title":"Stem Cell Rep"},{"key":"2748_CR60","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/leu.2011.235","volume":"26","author":"C Vicente","year":"2012","unstructured":"Vicente C, Vazquez I, Conchillo A, Garc\u00eda-S\u00e1nchez MA, Marcotegui N, Fuster O, et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia. 2012;26:550\u20134.","journal-title":"Leukemia"},{"key":"2748_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45691-4","volume":"15","author":"SG Kellaway","year":"2024","unstructured":"Kellaway SG, Potluri S, Keane P, Blair HJ, Ames L, Worker A, et al. Leukemic stem cells activate lineage inappropriate signalling pathways to promote their growth. Nat Commun. 2024;15:1359.","journal-title":"Nat Commun"},{"key":"2748_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/7724220","volume":"2022","author":"Y Luo","year":"2022","unstructured":"Luo Y, Xu Y, Li X, Shi X, Huang P, Chen Y, et al. A Prognostic Model of Seven Immune Genes to Predict Overall Survival in Childhood Acute Myeloid Leukemia. BioMed Res Int. 2022;2022:1\u201328.","journal-title":"BioMed Res Int"},{"key":"2748_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1000996","volume":"13","author":"M Luciano","year":"2022","unstructured":"Luciano M, Krenn PW, Horejs-Hoeck J. The cytokine network in acute myeloid leukemia. Front Immunol. 2022;13:1000996.","journal-title":"Front Immunol"},{"key":"2748_CR64","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13402-011-0017-9","volume":"34","author":"AC Weidenaar","year":"2011","unstructured":"Weidenaar AC, Ter Elst A, Koopmans-Klein G, Rosati S, Den Dunnen WFA, Meeuwsen-de Boer T, et al. High Acute Myeloid Leukemia derived VEGFA levels are associated with a specific vascular morphology in the leukemic bone marrow. Cell Oncol. 2011;34:289\u201396.","journal-title":"Cell Oncol"},{"key":"2748_CR65","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1182\/blood.V112.11.203.203","volume":"112","author":"AC Weidenaar","year":"2008","unstructured":"Weidenaar AC, Elst AT, De Jonge H-M, Boer TM, Kamps WA, De Bont ES. The role of VEGFA in malignant progression in AML. Blood. 2008;112:203\u2013203.","journal-title":"Blood"},{"key":"2748_CR66","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.2015.62.8289","volume":"33","author":"CM Zwaan","year":"2015","unstructured":"Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, et al. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33:2949\u201362.","journal-title":"J Clin Oncol"},{"key":"2748_CR67","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.3390\/cancers14153567","volume":"14","author":"MA Petersen","year":"2022","unstructured":"Petersen MA, Rosenberg CA, Bill M, Enemark MB, Rahbek O, Roug AS, et al. Proteomic profiling identifies specific leukemic stem cell-associated protein expression patterns in pediatric AML patients. Cancers. 2022;14:3567.","journal-title":"Cancers"},{"key":"2748_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33244-6","volume":"13","author":"BJ Huang","year":"2022","unstructured":"Huang BJ, Smith JL, Farrar JE, Wang Y-C, Umeda M, Ries RE, et al. Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia. Nat Commun. 2022;13:5487.","journal-title":"Nat Commun"},{"key":"2748_CR69","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1080\/16078454.2021.1917915","volume":"26","author":"Y Shi","year":"2021","unstructured":"Shi Y, He Z, Bei L, Tao H, Ding B, Tao S, et al. High expression of TARP correlates with inferior FLT3 mutations in non-adolescents and young adults with acute myeloid leukaemia. Hematology. 2021;26:380\u20137.","journal-title":"Hematology"},{"key":"2748_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.05.020","volume":"136","author":"F Millot","year":"2020","unstructured":"Millot F, Suttorp M, Versluys AB, Kalwak K, Nelken B, Ducassou S, et al. Ponatinib in childhood Philadelphia chromosome\u2013positive leukaemias: an international registry of childhood chronic myeloid leukaemia study. Eur J Cancer. 2020;136:107\u201312.","journal-title":"Eur J Cancer"},{"key":"2748_CR71","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16338","volume":"189","author":"J Rossoff","year":"2020","unstructured":"Rossoff J, Huynh V, Rau RE, Macy ME, Sulis ML, Schultz KR, et al. Experience with ponatinib in paediatric patients with leukaemia. Br J Haematol. 2020;189:363\u20138.","journal-title":"Br J Haematol"},{"key":"2748_CR72","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.3390\/cancers15071983","volume":"15","author":"A Trabal","year":"2023","unstructured":"Trabal A, Gibson A, He J, McCall D, Roth M, Nu\u00f1ez C, et al. Venetoclax for acute myeloid leukemia in pediatric patients: a Texas medical center experience. Cancers. 2023;15:1983.","journal-title":"Cancers"},{"key":"2748_CR73","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/S1470-2045(20)30060-7","volume":"21","author":"SE Karol","year":"2020","unstructured":"Karol SE, Alexander TB, Budhraja A, Pounds SB, Canavera K, Wang L, et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. Lancet Oncol. 2020;21:551\u201360.","journal-title":"Lancet Oncol"},{"key":"2748_CR74","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.3324\/haematol.2019.220962","volume":"105","author":"R Aplenc","year":"2020","unstructured":"Aplenc R, Meshinchi S, Sung L, Alonzo T, Choi J, Fisher B, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children\u2019s Oncology Group. Haematologica. 2020;105:1879\u201386.","journal-title":"Haematologica"},{"key":"2748_CR75","doi-asserted-by":"publisher","first-page":"409","DOI":"10.4103\/0377-4929.101761","volume":"55","author":"V Gadage","year":"2012","unstructured":"Gadage V, Galani K, Kadam Amare P, Mittal N. Systemic mastocytosis with associated acute myeloid leukemia with t (8; 21) (q22; q22). Indian J Pathol Microbiol. 2012;55:409.","journal-title":"Indian J Pathol Microbiol"},{"key":"2748_CR76","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13000-018-0691-2","volume":"13","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Nong L, Liang L, Wang W, Li T. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child. Diagn Pathol. 2018;13:14.","journal-title":"Diagn Pathol"},{"key":"2748_CR77","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.leukres.2013.04.020","volume":"37","author":"D Won","year":"2013","unstructured":"Won D, Chi H-S, Shim H, Jang S, Park C-J, Lee J-H. The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients. Leuk Res. 2013;37:883\u20138.","journal-title":"Leuk Res"},{"key":"2748_CR78","doi-asserted-by":"publisher","first-page":"6536","DOI":"10.1158\/1078-0432.CCR-05-0732","volume":"11","author":"WR Sperr","year":"2005","unstructured":"Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, J\u00e4ger U, Lechner K, et al. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res. 2005;11:6536\u201343.","journal-title":"Clin Cancer Res"}],"updated-by":[{"DOI":"10.1038\/s41375-025-02773-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02748-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02748-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02748-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:02:58Z","timestamp":1762336978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02748-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":78,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2748"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02748-7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41375-025-02773-6","URL":"https:\/\/doi.org\/10.1038\/s41375-025-02773-6","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods in this study were performed in accordance with the relevant guidelines and regulations. Single-cell RNA sequencing data sets were procured from publicly available repositories. Informed consent and institutional review board approval were obtained in the respective studies [\n                      \n                      \u2013\n                      \n                      ]. Ex vivo drug sensitivity studies were performed under informed consent and institutional review board approval (Emory University IRB #00034535).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}